Incidence of new and changed nevi and melanomas detected using baseline images and dermoscopy in patients at high risk for melanoma

Archives of Dermatology

Volumn 141, Issue 8, 2005, Pages 998-1006

  Banky, Jeremy P ^a,b   Kelly, John W ^a,b   English, Dallas R ^c   Yeatman, Josephine M ^a   Dowling, John P ^b  

^a Dermatology Unit   (Australia)

^b Victorian Melanoma Service   (Australia)

^c CANCER EPIDEMIOLOGY CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BIOPSY TECHNIQUE; CANCER INCIDENCE; CONTROLLED STUDY; DYSPLASTIC NEVUS; EPILUMINESCENCE MICROSCOPY; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; COHORT ANALYSIS; MIDDLE AGED; NEVUS; PATHOLOGY; PHOTOGRAPHY; PIGMENTED NEVUS; REMISSION; RISK FACTOR; SKIN TUMOR;

ADOLESCENT; ADULT; COHORT STUDIES; DERMOSCOPY; DYSPLASTIC NEVUS SYNDROME; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEVUS; NEVUS, PIGMENTED; PHOTOGRAPHY; REMISSION, SPONTANEOUS; RISK FACTORS; SKIN NEOPLASMS;

EID: 24044551673     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.141.8.998     Document Type: Article

References (36)

1. Kelly JW, Yeatman JM, Regalia C, Mason G, Henham AP. A high incidence of melanoma found in patients with multiple dysplastic naevi by photographic surveillance. Med J Aust. 1997;167:191-194.
2. Masri GD, Clark WH Jr, Guerry D IV, Halpern A, Thompson J, Elder DE. Screening and surveillance of patients at high risk for malignant melanoma result in detection of earlier disease. J Am Acad Dermatol. 1990;22:1042-1048.
3. Mackie RM, McHenry P, Hole D. Accelerated detection with prospective surveillance for cutaneous malignant melanoma in high-risk groups. Lancet. 1993;341:1618-1620.
4. Shriner DL, Wagner RF, Glowczwski JR. Photography for the early diagnosis of malignant melanoma in patients with atypical moles. Cutis. 1992;50:358-362.
5. Rivers JK, Kopf AW, Vinokur AF, et al. Clinical characteristics of malignant melanomas developing in persons with dysplastic nevi. Cancer. 1990;65:1232-1236.
6. Kopf AW, Rivers JK, Slue W, Rigel DS, Friedman RJ. Photographs are useful for detection of malignant melanomas in patients who have dysplastic nevi. J Am Acad Dermatol. 1988;19:1132-1134.
7. Tiersten AD, Grin CM, Kopf AW, et al. Prospective follow-up for malignant melanoma in patients with atypical-mole (dysplastic-mole) syndrome. J Dermatol Surg Oncol. 1991;17:44-48.
8. Holly EA, Kelly JW, Shpall SN, Chiu SH. Number of melanocytic nevi as a major risk factor for malignant melanoma. J Am Acad Dermatol. 1987;17:459-468.
9. Bataille V, Bishop JA, Sasieni P, et al. Risk of cutaneous melanoma in relation to the numbers, types and sites of naevi: a case-control study. Br J Cancer. 1996;73:1605-1611.
10. Bellet RE, Vaisman I, Mastrangelo MJ, Lustbader E. Multiple primary malignancies in patients with cutaneous melanoma. Cancer. 1977;40:1974-1981.
11. Beardmore GL, Davis NC. Multiple primary cutaneous melanomas. Arch Dermatol. 1975;111:603-609.
12. Holman CDJ, Armstrong BK. Pigmentary traits, ethnic origin, benign nevi, and family history risk factors for cutaneous malignant melanoma. J Natl Cancer Inst. 1984;72:257-266.
13. Ford D, Bliss JM, Swerdlow AJ, et al. Risk of cutaneous melanoma associated with a family history of the disease. Int J Cancer. 1995;62:377-381.
14. Kelly JW, Crutcher WA, Sagebiel RW. Clinical diagnosis of dysplastic melanocytic nevi: a clinicopathologic correlation. J Am Acad Dermatol. 1986;14:1044-1052.
15. Salopek TG, Kopf AW, Stefanato CM, Vossaert K, Silverman M, Yadav S. Differentiation of atypical moles (dysplastic nevi) from early melanomas by dermoscopy. Dermatol Clin. 2001;19:337-345.
16. McGovern VJ, Cochran AJ, Van Der Esch EP, Little JH, MacLennan R. The classification of malignant melanoma, its histological reporting and registration: a revision of the 1972 Sydney classification. Pathology. 1986;18:12-21.
17. Clark WH Jr, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behaviour of primary human malignant melanomas of the skin. Cancer Res. 1969;29:705-726.
18. Giles G, Whitfield K, Thursfield V, Staples M. Cancer in Victoria 1995. Melbourne, Australia: Anti-cancer Council of Victoria; 1998. Canstat 27.
19. Barnes LM, Nordlund JJ. The natural history of dysplastic nevi: a case history illustrating their evolution. Arch Dermatol. 1987;123:1059-1061.
20. Halpern AC, Guerry D IV, Elder DE, Trock B, Synnestvedt M, Humphreys T. Natural history of dysplastic nevi. J Am Acad Dermatol. 1993;29:51-57.
21. Stegmaier OC. Natural regression of the melanocytic nevus. J Invest Dermatol. 1959;32:413-420.
22. Lund HZ, Stobbe GD. The natural history of the pigmented nevus: factors of age and anatomic location. Am J Pathol. 1949;25:1117-1155.
23. Kelly JW, Rivers JK, MacLennan R, Harrison S, Lewis AE, Tate BJ. Sunlight: a major risk factor associated with the development of melanocytic nevi in Australian schoolchildren. J Am Acad Dermatol. 1994;30:40-48.
24. Nordlund JJ, Kirkwood J, Forget BM, et al. Demographic study of clinically atypical (dysplastic) nevi in patients with melanoma and comparison subjects. Cancer Res. 1985;45:1855-1861.
25. Grulich AE, Bataille V, Swerdlow AJ, et al. Naevi and pigmentary characteristics as risk factors for melanoma in a high-risk population: a case-control study in New South Wales, Australia. Int J Cancer. 1996;67:485-491.
26. Cooke KR, Spears GFS, Skegg DCG. Frequency of moles in a defined population. J Epidemiol Community Health. 1985;39:48-52.
27. Nicholls EM. Development and elimination of pigmented moles, and the anatomical distribution of primary malignant melanoma. Cancer. 1973;32:191-195.
28. Tucker MA, Halpern A, Holly EA, et al. Clinically recognized dysplastic nevi: a central risk factor for cutaneous melanoma. JAMA. 1997;277:1439-1444.
29. Kittler H, Pehamberger H, Wolff K, Binder M. Follow-up of melanocytic skin lesions with digital epiluminescence microscopy: patterns of modifications observed in early melanoma, atypical nevi, and common nevi. J Am Acad Dermatol. 2000;43:467-476.
30. Marks R, Jolley D, McCormack C, Dorevitch AP. Who removes pigmented skin lesions? a study of the ratio of melanoma to other benign pigmented tumors removed by different categories of physicians in Australia in 1989 and 1994. J Am Acad Dermatol. 1997;36:721-726.
31. Scott JP, Jolly KD, MacKinnon MJ, Clarke AM. Melanoma in Otago and Southland. N Z Med J. 1980;92:422-424.
32. Friedman RJ, Rigel DS, Kopf AW, et al. Favorable prognosis for malignant melanoma associated with acquired melanocytic nevi. Arch Dermatol. 1983;119:455-462.
33. Sagebiel RW. Histopathology of borderline and early malignant melanomas. Am J Surg Pathol. 1979;3:543-552.
34. Marks R, Dorevitch AP, Mason G. Do all melanomas come from "moles"? a study of the histological association between melanocytic naevi and melanoma. Australas J Dermatol. 1990;31:77-80.
35. Stolz W, Schmoeckel C, Landthaler M, Braun-Falco O. Association of early malignant melanoma with nevocytic nevi. Cancer. 1989;63:550-555.
36. Bevona C, Goggins W, Quinn T, Fullerton J, Tsao H. Cutaneous melanomas associated with nevi. Arch Dermatol. 2003;139:1620-1624.